FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2164796478> ?p ?o ?g. }

• W2164796478 endingPage "4" @default.
• W2164796478 startingPage "1" @default.
• W2164796478 abstract "Future CardiologyVol. 10, No. 1 EditorialFree AccessOptogenetics‘ promise: pacing and cardioversion by light?Christina M Ambrosi & Emilia EntchevaChristina M AmbrosiDepartment of Biomedical Engineering, Stony Brook University, BST6-120B, Stony Brook, NY 11794-8661, USASearch for more papers by this author & Emilia Entcheva* Author for correspondenceDepartment of Biomedical Engineering, Stony Brook University, BST6-120B, Stony Brook, NY 11794-8661, USA. Search for more papers by this authorEmail the corresponding author at entcheva@stonybrook.eduPublished Online:18 Dec 2013https://doi.org/10.2217/fca.13.89AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail Keywords: arrhythmiacardioversioncell therapydefibrillationgene therapyoptogeneticspacingElectronic device therapy: the current gold standard in cardiac arrhythmia managementElectronic device therapy (i.e., implantable pacemakers and cardioverter–defibrillators [ICDs]) is currently the gold standard in the management of cardiac arrhythmias. According to the most recent survey by the World Society of Arrhythmias, over 1 million pacemakers and 300,000 ICDs were implanted in 61 countries worldwide in 2009 [1]. All countries surveyed showed significant increases in implantation rates since 2005, and the global market for cardiac rhythm management devices is expected to reach US$15.2 billion by 2017.Cardiac pacemakers and ICDs are relatively safe and reliable, as evidenced by significant decreases in device malfunction rates since the early 1980s. However, limited battery life requires device replacements (with potential surgical complications) every 4–7 years [2]. Another major drawback of ICDs, in particular, is the pain associated with the high-energy shocks required to terminate tachyarrhythmias. The discomfort is caused by the shocks‘ nonspecific effects; for example, unintended contractions of noncardiac tissue (chest muscles, diaphragm and vocal cords). As a result, ICD recipients tend to have higher incidences of anxiety and depression than the general population [3]. An approach to pacing and cardioversion that is more cardiac tissue-specific and requires lower energy will reduce, or completely eliminate, the need for reimplantations (due to battery life) and reduce the pain and anxiety in ICD recipients. The nascent field of optogenetics may provide such opportunities for restoring normal heart rhythm painlessly, and subsequently increase quality of life for device recipients.Optogenetics‘ promise: the use of light for precise control of cellular functionOptogenetics is a new field of research using light to stimulate mammalian cells and tissues after genetic modification with microbial opsins (light-gated ion channels and pumps) [4]. It offers means for optical interrogation and control of biological function superior to traditional electrical and chemical stimulation; advantages include: • Targeted cellular control via promoter- and/or site-specified opsin expression;• High spatiotemporal resolution;• Versatility (i.e., excitatory and inhibitory effects can be encoded within the same cell for bidirectional control of membrane excitability);• The ability to stimulate with longer (low-light) pulses.Since 2005, optogenetic approaches have been widely used in neuroscience to dissect neural circuitry and gain insight into brain function in health and disease [5]. As an optical interrogation tool for basic science, optogenetics is very likely to have a profound impact on cardiac research (cardiac electrophysiology, arrhythmias, cell signaling and drug discovery) [6]. More recently, the use of optogenetics in experimental therapeutic control of brain activity, beyond basic research, shows promise and relevance to cardiac applications.Lessons from optical control of abnormal electrical activity in the brainEpileptic seizures and Parkinson‘s disease bear similarities to cardiac arrhythmias in that they are associated with aberrant electrical activity in regions of the brain. Current treatment options include deep-brain stimulation, a US FDA-approved electronic device therapy for the treatment of Parkinson‘s since 1997, which aims to alleviate symptoms by stimulating or electrically resetting specific regions with abnormal excitation. Recently, an optogenetics version of deep-brain stimulation has been explored as a means of optical stimulation of neural regions with more direct, cell-specific and effective perturbation, evoking the desired response (i.e., reduction or complete elimination of symptoms), while limiting undesired side effects seen in ‘blind‘, nonselective electrical stimulation [7]. Studies have also shown promise for closed-loop control of epileptic seizures by targeted on-demand optogenetic intervention in rodents [8]. Such cell-specific treatment strategies can spare cortical function and limit side effects not attainable by currently available electronic, pharmacological and surgical options. Parallels in antiarrhythmic therapy can be envisioned for the heart – eliminating noncardiac effects in an optical version of an ICD and/or lowering energies by specific targeting of opsin expression to certain cardiac cell types for optimal pacemaking.Cardiac optogenetics for pacing & cardioversion: translational challengesThe expansion of optogenetics to the cardiac field by our group and others is in very early stages [6,9–14]. It has, however, been demonstrated that the same opsins used in neuroscience can facilitate the optical stimulation of cardiac cells and tissues without negative electrophysiological effects and without the addition of exogenous cofactors at relatively low-light levels. If optogenetics can offer superior solutions to cardiac pacing and defibrillation, it is important to understand the potential hurdles to its translation as a clinical cardiac antiarrhythmia therapy.As optogenetics requires the genetic modification of tissue prior to optical stimulation, the safety and long-term efficiency of the delivery vehicle(s) must be addressed. Light sensitivity can be inscribed in cardiac cells or regions by either direct viral gene delivery or by cell delivery (opsin-carrying donor cells that couple to native myocytes). For both of these approaches, there is evidence for feasibility and potential success when applied to the heart based on ongoing clinical trials with other genes of interest [15–17].In addition to a transgenic animal approach [11,12] to cardiac optogenetics, direct viral delivery and functionality of opsins in cardiomyocytes has been demonstrated in vitro[13,18], including in adult cardiomyocytes [14]. Transduced heart cells maintain normal electrophysiology and respond to light pulses at low-light levels (0.1–5 mW/mm2). Recent clinical uses of gene therapy are focusing on adeno-associated viruses (AAVs) owing to certain advantages over other viral vectors, such as adenoviral and lentiviral, including lower mutagenicity, differential tissue tropism from 12 currently characterized serotypes, transduction of nondividing cells and long-term expression profiles [19]. Cardiac studies have reported long-term transgene expression, although the success of expression is intimately linked to viral dosing in order to achieve maximal transgene expression with minimal immune responses. Pre-existing immunity to specific AAV serotypes, however, can compromise transgene delivery; for instance, 72% of the worldwide population has neutralizing antibodies for AAV serotype 2 [20]. The development of ‘designer‘ AAV proteins with both enhanced tissue specificity and expression profiles may increase the feasibility of this approach in the larger population [20]. Cardiac clinical trials are ongoing, testing the efficacy of delivering SERCA2a, a Ca2+ ATPase, to the heart to reduce heart failure-related hospitalizations using AAV serotype 1 as a delivery vehicle (CUPID trial) [15]. In addition to efficacy, this study demonstrated safety – no reported adverse effects due to the administration of AAV1–SERCA2a. Therefore, AAV-mediated delivery of other transgenes, including opsins, to the heart may be a viable translational strategy.Feasibility for a potentially safer, nonviral cell-delivery approach to optogenetics was demonstrated in our recent in vitro study using a cell line stably expressing the excitatory opsin, ChR2, and relying on low-resistance cell coupling between the ChR2-expressing donor cells and host cardiomyocytes [10], requiring low energies (<0.5 mW/mm2). An in vivo strategy would involve autologous sources of somatic cells, such as fibroblasts or stem cells, optimized as opsin delivery vehicles, to mitigate immune responses. Although there is currently no FDA-approved somatic gene therapy, there are several ongoing clinical trials for cell delivery to the heart (e.g., SCIPIO [16] and CADUCEUS [17]). In all cases, for optogenetic applications, long-term studies must be undertaken to monitor the persistence of transgene (i.e., opsin) expression within the myocardium.Other outstanding challenges to the translation of cardiac optogenetics in vivo concern light delivery and optimization of the employed opsins. The ‘optogenetics toolbox‘ includes a rapidly growing compendium of mutant opsins for either excitation or inhibition of electrical activity that exhibit application-optimized kinetics and red-shifted spectral responses [21]. Red-shifted opsins are of particular interest in cardiac applications as the dense nature of the cardiac syncytium does not allow for deep penetration of shorter wavelengths of light and clinical optogenetic applications may be hampered by the selective sensitivity of ChR2 to blue light or other short-wavelength excitation spectra. Consequently, these alternative opsins [21], involving not only red-shifted light sensitivity, but also enhanced photocurrents, may allow for the engagement of deeper myocardial structures.Solutions to limited light penetration in the heart and the need for localized targeting will likely be sought through endoscopic routes using fiber optics. Computational optogenetics studies can provide proof-of-principle guidance and optimization to these challenges [9,14]. For example, energy for optical pacing can be reduced by cell-specific opsin expression and localized light delivery to the conduction system structures (e.g., Purkinje and His bundle) [9,14]. Cardioversion, however, unlike pacing, requires spatially distributed targeting in most cases and thus suitable light delivery. Nevertheless, the availability of both excitatory and inhibitory opsins and the ability to employ long pulses may provide new opportunities for control at lower energies. Furthermore, the miniaturization of optoelectronics, specifically light-emitting diodes, may offer fully integrated and possibly multisite actuation within the cardiac tissue itself, without the need to thread fiber optic illumination leads through the vasculature [22].Future perspectiveIn summary, we believe that optogenetics can be used to restore healthy heartbeats in patient populations requiring implantable devices. If energy benefits of optical control over conventional electronic devices are confirmed, it will present an attractive option in cardiac rhythm management as a strategy addressing battery life and pain reduction. In vivo testing of safety, efficacy and overall functionality in cardiac tissues are necessary, but if the hurdles discussed here can be surmounted, light-based antiarrhythmic therapies have the potential to offer significant improvements over traditional electronic device therapy.Financial & competing interests disclosureThis research was supported by a US NIH grant R01-HL111649. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.References1 Mond HG, Proclemer A. The 11th world survey of cardiac pacing and implantable cardioverter–defibrillators: calendar year 2009 – a world society of arrhythmia‘s project. Pacing Clin. Electrophysiol.34(8),1013–1027 (2011).Crossref, Medline, Google Scholar2 Hauser RG, Hayes DL, Kallinen LM et al. Clinical experience with pacemaker pulse generators and transvenous leads: an 8-year prospective multicenter study. Heart Rhythm4(2),154–160 (2007).Crossref, Medline, Google Scholar3 Baumert J, Schmitt C, Ladwig KH. Psychophysiologic and affective parameters associated with pain intensity of cardiac cardioverter defibrillator shock discharges. Psychosom. Med.68(4),591–597 (2006).Crossref, Medline, Google Scholar4 Deisseroth K, Feng G, Majewska AK, Miesenbock G, Ting A, Schnitzer MJ. Next-generation optical technologies for illuminating genetically targeted brain circuits. J. Neurosci.26(41),10380–10386 (2006).Crossref, Medline, CAS, Google Scholar5 Yizhar O, Fenno LE, Davidson TJ, Mogri M, Deisseroth K. Optogenetics in neural systems. Neuron71(1),9–34 (2011).Crossref, Medline, CAS, Google Scholar6 Entcheva E. Cardiac optogenetics. Am. J. Physiol. Heart Circ. Physiol.304(9),H1179–H1191 (2013).Crossref, Medline, CAS, Google Scholar7 Gradinaru V, Mogri M, Thompson KR, Henderson JM, Deisseroth K. Optical deconstruction of parkinsonian neural circuitry. Science324(5925),354–359 (2009).Crossref, Medline, CAS, Google Scholar8 Krook-Magnuson E, Armstrong C, Oijala M, Soltesz I. On-demand optogenetic control of spontaneous seizures in temporal lobe epilepsy. Nat. Commun.4,1376 (2013).Crossref, Medline, Google Scholar9 Boyle PM, Williams JC, Ambrosi CM, Entcheva E, Trayanova NA. A comprehensive multiscale framework for simulating optogenetics in the heart. Nat. Commun.4,2370 (2013).Crossref, Medline, Google Scholar10 Jia Z, Valiunas V, Lu Z et al. Stimulating cardiac muscle by light: cardiac optogenetics by cell delivery. Circ. Arrhythm. Electrophysiol.4(5),753–760 (2011).Crossref, Medline, Google Scholar11 Arrenberg AB, Stainier DY, Baier H, Huisken J. Optogenetic control of cardiac function. Science330(6006),971–974 (2010).Crossref, Medline, CAS, Google Scholar12 Bruegmann T, Malan D, Hesse M et al. Optogenetic control of heart muscle in vitro and in vivo. Nat. Methods7(11),897–900 (2010).Crossref, Medline, CAS, Google Scholar13 Abilez OJ, Wong J, Prakash R, Deisseroth K, Zarins CK, Kuhl E. Multiscale computational models for optogenetic control of cardiac function. Biophys. J.101(6),1326–1334 (2011).Crossref, Medline, CAS, Google Scholar14 Williams JC, Xu J, Lu Z et al. Computational optogenetics: empirically-derived voltage-and light-sensitive channelrhodopsin-2 model. PLoS Comput. Biol.9(9),e1003220 (2013).Crossref, Medline, CAS, Google Scholar15 Jessup M, Greenberg B, Mancini D et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a Phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation124(3),304–313 (2011).Crossref, Medline, CAS, Google Scholar16 Bolli R, Chugh AR, D‘Amario D et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised Phase 1 trial. Lancet378(9806),1847–1857 (2011).Crossref, Medline, Google Scholar17 Makkar RR, Smith RR, Cheng K et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised Phase 1 trial. Lancet379(9819),895–904 (2012).Crossref, Medline, Google Scholar18 Ambrosi CM, Chen K, Kalra J et al. Distribution of donor cells alters energy requirements for optogenetic control of the heart. Heart Rhythm10(5),S96 (2013).Crossref, Google Scholar19 Williams PD, Ranjzad P, Kakar SJ, Kingston PA. Development of viral vectors for use in cardiovascular gene therapy. Viruses2(2),334–371 (2010).Crossref, Medline, CAS, Google Scholar20 Hareendran S, Balakrishnan B, Sen D, Kumar S, Srivastava A, Jayandharan GR. Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them. Rev. Med. Virol.23(6),399–413 (2013).Crossref, Medline, CAS, Google Scholar21 Lin JY, Knutsen PM, Muller A, Kleinfeld D, Tsien RY. ReaChR: a red-shifted variant of channelrhodopsin enables deep transcranial optogenetic excitation. Nat. Neurosci.16(10),1499–1508 (2013).Crossref, Medline, CAS, Google Scholar22 Kim TI, McCall JG, Jung YH et al. Injectable, cellular-scale optoelectronics with applications for wireless optogenetics. Science340(6129),211–216 (2013).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByOptogenetics for light control of biological systems21 July 2022 | Nature Reviews Methods Primers, Vol. 2, No. 1Optogenetic Stimulation Using Anion Channelrhodopsin (GtACR1) Facilitates Termination of Reentrant Arrhythmias With Low Light Energy Requirements: A Computational Study30 August 2021 | Frontiers in Physiology, Vol. 12Shining light on cardiac electrophysiology: From detection to intervention, from basic research to translational applicationsLife Sciences, Vol. 274Cardiac optogenetics: a decade of enlightenment18 December 2020 | Nature Reviews Cardiology, Vol. 18, No. 5Non-invasive red-light optogenetic control of Drosophila cardiac function29 June 2020 | Communications Biology, Vol. 3, No. 1Cardiac Optogenetics in Atrial Fibrillation: Current Challenges and Future OpportunitiesBioMed Research International, Vol. 2020Optogenetics: Background, Methodological Advances and Potential Applications for Cardiovascular Research and Medicine29 January 2020 | Frontiers in Bioengineering and Biotechnology, Vol. 7 Optogenetic Pacing: Current Insights and Future Potential 1 November 2020 | Research Reports in Clinical Cardiology, Vol. Volume 11Energy-Reduced Arrhythmia Termination Using Global Photostimulation in Optogenetic Murine Hearts27 November 2018 | Frontiers in Physiology, Vol. 9Termination of re‐entrant atrial tachycardia via optogenetic stimulation with optimized spatial targeting: insights from computational models28 December 2017 | The Journal of Physiology, Vol. 596, No. 2Will cardiac optogenetics find the way through the obscure angles of heart physiology?Biochemical and Biophysical Research Communications, Vol. 482, No. 4Anion channelrhodopsins for inhibitory cardiac optogenetics15 September 2016 | Scientific Reports, Vol. 6, No. 1Inhibitory luminopsins: genetically-encoded bioluminescent opsins for versatile, scalable and hardware-independent optogenetic inhibition24 September 2015 | Scientific Reports, Vol. 5, No. 1Channelrhodopsin2 Current During the Action Potential: “Optical AP Clamp” and Approximation25 July 2014 | Scientific Reports, Vol. 4, No. 1Optogenetic versus Electrical Stimulation of Human Cardiomyocytes: Modeling InsightsBiophysical Journal, Vol. 108, No. 8Optogenetics-enabled dynamic modulation of action potential duration in atrial tissue: feasibility of a novel therapeutic approach31 October 2014 | Europace, Vol. 16, No. suppl 4Cardiac applications of optogeneticsProgress in Biophysics and Molecular Biology, Vol. 115, No. 2-3Fiat lux in understanding cardiac pacing, resynchronization and signalling by way of optogenetics22 April 2014 | Cardiovascular Research, Vol. 102, No. 3 Vol. 10, No. 1 Follow us on social media for the latest updates Metrics History Published online 18 December 2013 Published in print January 2014 Information© Future Medicine LtdKeywordsarrhythmiacardioversioncell therapydefibrillationgene therapyoptogeneticspacingFinancial & competing interests disclosureThis research was supported by a US NIH grant R01-HL111649. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download" @default.
• W2164796478 created "2016-06-24" @default.
• W2164796478 creator A5016192754 @default.
• W2164796478 creator A5048078446 @default.
• W2164796478 date "2014-01-01" @default.
• W2164796478 modified "2023-10-14" @default.
• W2164796478 title "Optogenetics‘ promise: pacing and cardioversion by light?" @default.
• W2164796478 cites W1508695273 @default.
• W2164796478 cites W1822742328 @default.
• W2164796478 cites W1964617104 @default.
• W2164796478 cites W1966714298 @default.
• W2164796478 cites W1976011628 @default.
• W2164796478 cites W1978253480 @default.
• W2164796478 cites W1978762517 @default.
• W2164796478 cites W2001406655 @default.
• W2164796478 cites W2037594700 @default.
• W2164796478 cites W2038439610 @default.
• W2164796478 cites W2042110107 @default.
• W2164796478 cites W2050932531 @default.
• W2164796478 cites W2083932518 @default.
• W2164796478 cites W2088186055 @default.
• W2164796478 cites W2116744112 @default.
• W2164796478 cites W2123490348 @default.
• W2164796478 cites W2132735690 @default.
• W2164796478 cites W2144327104 @default.
• W2164796478 cites W2151781534 @default.
• W2164796478 cites W2167237768 @default.
• W2164796478 cites W4211248224 @default.
• W2164796478 cites W4237572359 @default.
• W2164796478 doi "https://doi.org/10.2217/fca.13.89" @default.
• W2164796478 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4035099" @default.
• W2164796478 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24344652" @default.
• W2164796478 hasPublicationYear "2014" @default.
• W2164796478 type Work @default.
• W2164796478 sameAs 2164796478 @default.
• W2164796478 citedByCount "20" @default.
• W2164796478 countsByYear W21647964782014 @default.
• W2164796478 countsByYear W21647964782015 @default.
• W2164796478 countsByYear W21647964782016 @default.
• W2164796478 countsByYear W21647964782017 @default.
• W2164796478 countsByYear W21647964782018 @default.
• W2164796478 countsByYear W21647964782020 @default.
• W2164796478 countsByYear W21647964782021 @default.
• W2164796478 countsByYear W21647964782022 @default.
• W2164796478 countsByYear W21647964782023 @default.
• W2164796478 crossrefType "journal-article" @default.
• W2164796478 hasAuthorship W2164796478A5016192754 @default.
• W2164796478 hasAuthorship W2164796478A5048078446 @default.
• W2164796478 hasBestOaLocation W21647964782 @default.
• W2164796478 hasConcept C126322002 @default.
• W2164796478 hasConcept C164705383 @default.
• W2164796478 hasConcept C169760540 @default.
• W2164796478 hasConcept C2777289489 @default.
• W2164796478 hasConcept C2779161974 @default.
• W2164796478 hasConcept C50738837 @default.
• W2164796478 hasConcept C71924100 @default.
• W2164796478 hasConcept C86803240 @default.
• W2164796478 hasConceptScore W2164796478C126322002 @default.
• W2164796478 hasConceptScore W2164796478C164705383 @default.
• W2164796478 hasConceptScore W2164796478C169760540 @default.
• W2164796478 hasConceptScore W2164796478C2777289489 @default.
• W2164796478 hasConceptScore W2164796478C2779161974 @default.
• W2164796478 hasConceptScore W2164796478C50738837 @default.
• W2164796478 hasConceptScore W2164796478C71924100 @default.
• W2164796478 hasConceptScore W2164796478C86803240 @default.
• W2164796478 hasIssue "1" @default.
• W2164796478 hasLocation W21647964781 @default.
• W2164796478 hasLocation W21647964782 @default.
• W2164796478 hasLocation W21647964783 @default.
• W2164796478 hasLocation W21647964784 @default.
• W2164796478 hasOpenAccess W2164796478 @default.
• W2164796478 hasPrimaryLocation W21647964781 @default.
• W2164796478 hasRelatedWork W1531601525 @default.
• W2164796478 hasRelatedWork W2021703221 @default.
• W2164796478 hasRelatedWork W2758277628 @default.
• W2164796478 hasRelatedWork W2935909890 @default.
• W2164796478 hasRelatedWork W2948807893 @default.
• W2164796478 hasRelatedWork W3173606202 @default.
• W2164796478 hasRelatedWork W3183948672 @default.
• W2164796478 hasRelatedWork W4206570293 @default.
• W2164796478 hasRelatedWork W2778153218 @default.
• W2164796478 hasRelatedWork W3110381201 @default.
• W2164796478 hasVolume "10" @default.
• W2164796478 isParatext "false" @default.
• W2164796478 isRetracted "false" @default.
• W2164796478 magId "2164796478" @default.
• W2164796478 workType "article" @default.